Characterizing the broad spectrum of pathogenic and non-pathogenic CFTR variants across ancestries holds promise to revolutionize molecular diagnoses of CF and could enable wider access to personalized CFTR modulator therapies. This evidence concerns the gene CFTR and cystic fibrosis.